Exebacase

DB16161Investigational

Exebacase is under investigation in clinical trial NCT03163446 (Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia).

Mechanism: Pharmacologically active on Bacterial cell wall peptide bridging segments
Curator reviewed
Also known as: Des-met1-putative phage lysin (streptococcus phage phi891591), produced in escherichia coli · Lysin cf-301 (streptococcus suis phage) · Lysin plyss2 (streptococcus suis phage)
Code names: CF-301

Resolves to

Compound

UNII67F0M5CY5YCAS1404122-92-4

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Exebacase, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account